Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Iterum Therapeutics plc logo — Iterum develops anti-infectives to combat multi-drug resista...

Iterum Therapeutics plc

Iterum develops anti-infectives to combat multi-drug resistant pathogens and serious infections inadequately addressed by current therapies.

Founded 2015 Ireland Ireland 16 employees Post Ipo Equity Total: $193.40M Health and Wellness, Pharmaceutical

General Information

Company Name Iterum Therapeutics plc
Founded Year 2015
Location Ireland Ireland +3
Founders / Decision Makers
Team member Team member
Employees 16
Industries Health and Wellness, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Iterum Therapeutics plc moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Iterum Therapeutics plc

Iterum Therapeutics plc, a Dublin-based pharmaceutical company established in 2015, is dedicated to tackling the pressing issue of multi-drug resistance (MDR) pathogens. The company's slogan emphasizes its focus on developing anti-infectives to combat MDR pathogens and serious infections inadequately addressed by current therapies. Iterum Therapeutics aims to improve the quality of life for patients suffering from severe and life-threatening diseases globally through its innovative approach. The organization's commitment to addressing unmet needs in the treatment of severe infections, as identified by the Centers for Disease Control and Prevention (CDC), sets it apart in the pharmaceutical industry. The company has recently secured a significant $35.00M post-IPO equity investment on 03 February 2021, illustrating the confidence of investors in Iterum Therapeutics' mission and potential. This substantial investment further validates the market's recognition of the company's efforts to combat MDR pathogens and improve treatment options for serious infections. With its headquarters in Ireland, Iterum Therapeutics is well-positioned to advance its clinical-stage pharmaceutical developments and make a meaningful impact on global healthcare.

Taxonomy: anti-infectives, multi-drug resistant pathogens, serious infections, clinical-stage pharmaceutical company, innovative treatments, multi-drug resistance (MDR), patient quality of life, severe infections, drug development, anti-microbial resistance, CDC, Dublin-based company

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 03 Feb 2021
Post-IPO Equity •••••• 2
Investor Investor
17 Jan 2020
Grant •••••• 1
Investor
01 Jul 2017
Series B •••••• 9
Investor Investor Investor Investor Investor Investor Investor Investor Investor
19 May 2017
Series A •••••• 4
Investor Investor Investor Investor
24 Mar 2016

View All 6 Funding Rounds

Iterum Therapeutics plc Alternatives & Competitors

Iterum Therapeutics plc vs
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. United States

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-tre...

Unknown
33 employees
Health Care, Pharmaceutical
Iterum Therapeutics plc vs
Biocidium Biopharmaceuticals
Biocidium Biopharmaceuticals Canada

Clinical-stage biopharmaceutical company focused on novel antibiotics, antifungals, and treatments f...

1 employees
Biopharma, Biotechnology
Iterum Therapeutics plc vs
Atterx BioTherapeutics, Inc.
Atterx BioTherapeutics, Inc.

Proprietary products for the prevention and treatment of multi-drug resistant Gram negative bacteria...

Series C
4 employees
Biopharma, Biotechnology

FAQ About Iterum Therapeutics plc

Iterum develops anti-infectives to combat multi-drug resistant pathogens and serious infections inadequately addressed by current therapies.
Iterum Therapeutics plc was founded in 2015.
Iterum Therapeutics plc is headquartered in Ireland.
Iterum Therapeutics plc operates in the following industries: Health and Wellness, Pharmaceutical.
Iterum Therapeutics plc has approximately 16 employees.
Iterum Therapeutics plc has completed 6 funding rounds, raising a total of $193.40M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Iterum Therapeutics plc include Venatorx Pharmaceuticals, Inc., Biocidium Biopharmaceuticals, Atterx BioTherapeutics, Inc., Techulon Inc., Prokaryotics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Iterum Therapeutics plc and Venatorx Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Iterum Therapeutics plc and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy